GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

NCT04944888 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
Hematologic Malignancy

Interventions

DRUG: Eliglustat
DRUG: Immune checkpoint inhibitor

Sponsor

Chinese PLA General Hospital